Core Viewpoint - Mees Health (02415.HK) announced that its subsidiary, Shanghai Mees Pharmaceutical Technology Co., Ltd., has won a large real-world research project from a Chinese pharmaceutical company, focusing on the efficacy and safety of IL-1β monoclonal antibody treatment for gout patients [1] Group 1 - The project aims to systematically evaluate the effectiveness and safety of IL-1β monoclonal antibody treatment for patients during both acute and intercritical phases of gout through a combination of prospective and retrospective observational studies [1] - The project is valued at approximately RMB 21 million [1] - The group leverages over a decade of experience in its internet doctor platform, utilizing big data and artificial intelligence technologies to connect doctors, patients, and medical device companies, thereby providing digital solutions to enhance the healthcare ecosystem and improve medical quality [1]

Core Viewpoint - Mees Health (02415) announced that its subsidiary, Shanghai Mees Pharmaceutical Technology Co., Ltd., has won a large real-world research project from a Chinese pharmaceutical company, focusing on the efficacy and safety of IL-1β monoclonal antibody treatment for acute and intercritical gout patients [1] Group 1 - The project amount is approximately RMB 21 million [1] - The project aims to systematically evaluate the effectiveness and safety of the treatment through a combination of prospective and retrospective observational studies [1] Group 2 - The company leverages over ten years of experience in its internet doctor platform, utilizing big data and artificial intelligence technologies to connect doctors, patients, and medical device companies [1] - The digital solutions provided by the company aim to empower the medical ecosystem and improve healthcare quality [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本集團依託於積累十餘年的互聯網醫生平台，應用大數據和人工智能技術鏈接醫 生、患者和藥械企業，提供數字化解決方案，賦能醫療生態，改善醫療質量。 承董事會命 梅斯健康控股有限公司 MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2415） 自願性公告 中標 中國某藥企「痛風智管計劃」大型真實世界研究項目 本公告由梅斯健康控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」）自願 發佈，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，近期，本公司的子公司上海梅斯醫藥 科技有限公司中標中國某藥企的一項大型真實世界研究項目，該項目旨在「透過前 瞻性與回顧性相結合的觀察性研究，系統評估IL-1β單抗治療痛風急性期與間歇期 患者的有效性與安全性」，項目金額為約人民幣2, ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 梅斯健康控股有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02415 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | USD | | 0.0001 USD | | 1,500,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 15,000,000,000 | USD | | 0.0001 USD | | 1,500,000 | 本月 ...

Core Viewpoint - Meis Health (02415) announced a mid-term dividend of HKD 0.011 per share for the six months ending June 30, 2025, to be distributed on October 30, 2025 [1] Company Summary - The company will distribute the mid-term dividend on October 30, 2025 [1] - The dividend pertains to the financial period ending June 30, 2025 [1]

Group 1 - The company, Meis Health (02415), announced a mid-term dividend of HKD 0.011 per share for the six months ending June 30, 2025, to be distributed on October 30, 2025 [1]

EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，董事會包括執行董事為張發寶博士、李欣梅博士、王帥先生及程亮先生；非執行董事為王欣女士及閆盛楓先生；以 及獨立非執行董事為劉濤女士、余明陽先生及劉耀坤先生。 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 梅斯健康控股有限公司 | | 股份代號 | 02415 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月之中期股息 | | 公告日期 | 2025年9月1日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 | 股息不涉及代扣所得稅 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 ...

Core Insights - The company, Meis Health (02415.HK), reported total revenue of RMB 125.2 million for the six months ending June 30, 2025, representing a year-on-year growth of 13.2% [1] - Gross profit reached RMB 77.5 million, with a year-on-year increase of 14.1% [1] - Net profit surged to RMB 13.2 million, reflecting an extraordinary year-on-year growth of 5,238.3% [1] Revenue Drivers - The growth in performance is primarily attributed to the industry's recovery, which has driven an increase in demand for multi-channel precision marketing [1] - Companies are accelerating their transition to evidence-driven marketing models, contributing to the revenue growth [1] Operational Efficiency - The increase in gross and net profits is supported by the establishment of an AI-driven intelligent operation system, which has enhanced efficiency and optimized sales strategies [1] - Notably, revenue from AI-related businesses reached RMB 5.6 million during the reporting period, marking it as a significant source of new growth for the company [1]

Core Viewpoint - Meiz Health (02415) reported a significant increase in both revenue and net profit for the first half of 2025, driven by the recovery in the pharmaceutical industry and the accelerated transformation of domestic pharmaceutical companies towards evidence-driven marketing models [1] Financial Performance - Revenue reached 125 million RMB, representing a year-on-year growth of 13.2% [1] - Net profit amounted to 13.239 million RMB, showing a remarkable year-on-year increase of 5238.3% [1] - Basic earnings per share were 2.45 cents, with a proposed interim dividend of 1.1 Hong Kong cents per share [1] Industry Trends - The growth in total revenue is attributed to the recovery in the pharmaceutical sector [1] - There is an increasing demand for precision omnichannel marketing solutions, driven by the transformation of domestic pharmaceutical companies [1]

Core Viewpoint - Meiz Health (02415) reported a mid-year performance for 2025, showing significant growth in both revenue and net profit, driven by the recovery in the pharmaceutical industry and the shift towards evidence-driven marketing models in domestic pharmaceutical companies [1] Financial Performance - Revenue reached 125 million RMB, representing a year-on-year increase of 13.2% [1] - Net profit amounted to 13.239 million RMB, reflecting a remarkable year-on-year growth of 5238.3% [1] - Basic earnings per share were 2.45 cents, with an interim dividend proposed at 1.1 Hong Kong cents per share [1] Industry Trends - The increase in total revenue is primarily attributed to the recovery in the pharmaceutical sector [1] - There is a growing demand for precision omnichannel marketing solutions, driven by the accelerated transformation of domestic pharmaceutical companies towards evidence-driven marketing models [1]